Celularity Inc Income Statement
CELU|5 years of annual SEC 10-K data (FY2021-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
Celularity Inc reported $27M in revenue and $92M in net loss for FY2025. Revenue has grown at a 5.6% compound annual rate over the past 4 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -9.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $26.6M | $54.2M | $22.8M | $18.0M | $21.3M |
| Cost of Revenue | $20.1M | $15.0M | $16.0M | - | - |
| Gross Profit | - | - | $6.8M | -$1.7M | $11.7M |
| SG&A Expense | $51.3M | $58.6M | $50.6M | $66.0M | $71.3M |
| R&D Expense | $15.0M | $17.4M | $30.5M | $78.4M | $88.4M |
| Operating Income | -$61.3M | -$38.4M | -$192.3M | -$25.6M | -$109.1M |
| Income Tax | $3.0K | - | $10.0K | $13.0K | $20.0K |
| Net Income | -$91.7M | -$57.9M | -$196.3M | $14.2M | -$100.1M |
| EPS (Basic) | -$2.64 | -$11.02 | $1.01 | -$1.49 | - |
| EPS (Diluted) | -$2.64 | -$11.02 | $0.95 | -$1.49 | -$11.31 |
| Shares Outstanding | 22.5M | 19.4M | 14.9M | 124.3M | 18.5M |
| Gross Margin | - | - | 29.7% | -9.4% | 54.8% |
| Operating Margin | -230.9% | -70.8% | -844.4% | -142.4% | -511.2% |
| Profit Margin | -345.4% | -106.8% | -862.0% | 79.0% | -469.3% |